Various speakers invited to the congress discussed the CRISPR-Cas9 system and its use for future clinical applications. Key point often brought up was the delivery tool to carry the CRISPR-Cas 9 system in a safe and efficient way. Because the CRISPR-Cas 9 stable expression may result in off-target effects, many scientists choose transient RNA delivery tools.
The information gathered at the congress strengthened our view presented in the poster: our non-integrative RNA delivery particle Lentiflash differs from all existing systems and meets all the requirements for an efficient and safe delivery of the CRISPR-Cas 9 system.
Gene knock-out with LentiFlash carrying CRISPR-Cas9 system:
Highly concentrated and purified at Vectalys, our new particle is able to deliver non-viral coding or non-coding RNA at high efficiency. Our poster shows the ability of the LentiFlash particle to deliver the CRISPR-Cas9 system in different types of cells without affecting viability, including human primary T lymphocytes, preserving the original phenotype of the cells. Three points are approached:
- LentiFlash: a new tool for efficient and transient CRISPR-Cas9 delivery
- Highly efficient disruption of PD-1 in human primary T-cells using CRISPR-Cas9
- LentiFlash: benefits from lentiviral vector properties without genomic trace
To discover our poster click here .